Evidence map›Paper›PMID 37035017›Full record

ArticleAnalytical cellular pathology (Amsterdam)2023

Inhibition of miR-182-5p Targets FGF9 to Alleviate Osteoarthritis.

Yang Sun, Sanmao Su, Mengjun Li, Ang Deng

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yang SunDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital Central South University, Changsha, China.
Sanmao SuPhase I Clinical Trial Center, Xiangya Hospital Central South University, Changsha, China.
Mengjun LiDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital Central South University, Changsha, China.
Ang DengDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-3463-4330
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The pathogenesis of osteoarthritis (OA) is complex and there is no specific drug for treatment. The aim of this study was to identify the molecular targets of OA therapy, focusing on the expression and biological functions of miR-182-5p and its target genes in OA. Methods: miR-182-5p and fibroblast growth factor 9 (FGF9) were overexpressed or knocked down in IL-1 Results: The expression of miR-182-5p was upregulated, and FGF9 was downregulated in the IL-1 Conclusions: miR-182-5p expression levels were increased in OA chondrocytes and regulated chondrocyte proliferation, apoptosis, and inflammation by targeting FGF9. miR-182-5p is a potential gene for OA treatment.

Indexed as

MicroRNAsOsteoarthritisAnimalsApoptosisChondrocytesFibroblast Growth Factor 9InflammationInterleukin-1betaInterleukin-6RatsFgf9 protein, ratFibroblast Growth Factor 9Interleukin-1betaInterleukin-6MicroRNAsMIRN182 microRNA, rat

Identifiers

PMID37035017
PMCPMC10076120
OpenAlexW4361298630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.